Effects of sodium-glucose co-transporter 2 inhibitor on metabolic parameters in patients with type 2 diabetes
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Canagliflozin (Primary) ; Dapagliflozin (Primary) ; Empagliflozin (Primary) ; Luseogliflozin (Primary) ; Tofogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 27 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 05 Apr 2017 Planned no of patients changed from 85 to 150.
- 05 Apr 2017 Status changed from completed to recruiting.